Company Overview and News
Second quarter earnings season saw another robust period of upside surprises and bottom-line growth, but tepid guidance in certain industries and external issues like trade disputes kept gains at bay. Now, as we move into a quiet period for earnings, thesame external factors will weigh on the minds of investors, and those reporting during this stretch will need to seriously impress.
bluebird bio, Inc. (BLUE - Free Report) announced updated results from phase II/III Starbeam study (ALD-102) of its investigational Lenti-D gene therapy in boys aged 17 years or below with cerebral adrenoleukodystrophy (CALD). The company also announced initial results from the ongoing observational ALD-103 study of outcomes from allogeneic hematopoietic stem cell transplant (allo-HSCT) in boys aged 17 years or below with CALD.
CELGZ GILD BLUE LGNDZ TJX LGNZZ CELG LGND KHC LGNYZ LGNXZ BLUE
2018-08-22 seekingalpha - 1
bluebird bio is a clinical-stage biotechnology company focussed on gene therapy, cancer immunopathy and gene editing for the treatment of cancer and rare diseases.
MBIO REGN GILD JUNO BLUE CELG NVS KITE BLUE CR
The key headlines in the biotech sector this week include Regeneron Pharmaceuticals’ (REGN - Free Report) strong Q2 results and its $100 million investment in bluebird bio (BLUE - Free Report) . Meanwhile, among regular pipeline and regulatory updates, Gilead (GILD - Free Report) is making further inroads into China with its HIV franchise.
VRTX REGN ELY ICFI BLUE BLUE ONCE
On today’s episode of Free Lunch, Associate Stock Strategist Ryan McQueeney highlights today’s trending stories, including the departure of PepsiCo’s CEO, Jamie Dimon’s latest public wisdom, and Bluebird Bio’s new partnership. Later, he recaps recent developments in the T-Mobile-Sprint merger and previews what the combined company might look like.
REGN S PEP BLUE BLUE GTLS
Shares of Bluebird Bio (BLUE - Free Report) gained in morning trading Monday after the company announced a new partnership with Regeneron Pharmaceuticals (REGN - Free Report) . The five-year agreement will see both firms collaborate on new cell therapies for the treatment of cancer.
REGN BLUE BLUE
bluebird bio, Inc. (BLUE - Free Report) reported a loss of $2.91 per share, much wider than the Zacks Consensus Estimate of a loss of $2.30 and the year-ago loss of $1.73. The wider-than-expected loss was due to higher research & development (R&D) and general & administrative (G&A) expenses on lower revenues.
CELGZ BLUE CELG NVS BLUE
Humana Inc.’s (HUM - Free Report) second-quarter 2018 results, scheduled to be reported on Aug 1, 2018, has likely witnessed an increase in individual Medicare Advantage membership strength, driven by strong segmental performances. Additionally, the company has likely expanded into different geographical regions of their value-based primary care and Management Services Organization (MSO) support models.
ETR ALGN XRAY BLUE BLUE HUM AQB
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...
2018-09-18 - Asif
Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...
2018-09-18 - Asif
Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...
Silicon Investor Message Boards
This table lists all message boards related to EPA:BLUE / BLUE on message board site Silicon Investor.